Bill No. 2801, introduced by Representatives Marti and Stanley, amends Section 204 of the Oklahoma Health Care Authority's vendor drug program. The bill authorizes the Authority to approve prior authorization requests for atypical antipsychotic medications that are not on the preferred drug list, specifically for the treatment and prevention of mood disorders with psychotic symptoms, including bipolar disorders and schizophrenia. The approval process will consider the patient's claims history or healthcare provider attestation, requiring either a trial and failure of any preferred atypical antipsychotic within the past year or confirmation that the patient is stable on a non-preferred atypical antipsychotic.

Additionally, the bill ensures that medications approved under this section will be available at parity with other branded medications in the same class. The act is set to take effect on November 1, 2025.